AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.97
+0.17%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 75.93x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 1.72x
- Price / sales
- 82.74x
- Price / cash flow
- -11.05x
Enterprise value
- Enterprise value
- $326.3M
- EV / sales
- 32.43x
- EV / EBITDA
- -4.20x
- EV / EBIT
- -3.74x
- Market cap
- $832.3M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026